MTOR and ovarian cancer: Cardamonin’s impact on both mTOR and STAT3 pathways emphasizes its role as a potential therapeutic agent that could disrupt TAMs’ support of ovarian cancer, offering a promising avenue for enhancing immunotherapy in this challenging cancer type (186).